New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants

Peer Review reports

Original Submission
10 Mar 2023	Submitted	Original manuscript
26 Mar 2023	Reviewed	Reviewer Report
29 Mar 2023	Reviewed	Reviewer Report
31 Mar 2023	Author responded	Author comments - Padmini Srikantiah
Resubmission - Version 2
31 Mar 2023	Submitted	Manuscript version 2
22 Apr 2023	Author responded	Author comments - Padmini Srikantiah
Resubmission - Version 3
22 Apr 2023	Submitted	Manuscript version 3
Publishing
27 Apr 2023	Editorially accepted
15 May 2023	Article published	10.1186/s12916-023-02883-x

Back to article page